⌘K
t
On 09 June 2026, Thalia Therapeutics plc announced it shared a new article titled 'RNA medicine enters its second act' in European Biotechnology Magazine's RNA Therapeutics Special. The article includes a discussion by Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, on the Company's strategic focus on RNA therapeutics, new RNA modalities, and therapeutic areas.
9 June 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
New article: RNA medicine enters its second act
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA therapeutics, is pleased to share a new article, 'RNA medicine enters its second act', in European Biotechnology Magazine's RNA Therapeutics Special.
The RNA therapeutics market continues to gather momentum, presenting significant opportunities for innovation and value creation. Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, discusses the Company's strategic focus on RNA therapeutics, the potential for new RNA modalities including microRNAs and the opportunity to address new therapeutic areas such as cardiovascular disease and oncology.
Link to the article: https://issuu.com/biocom/docs/ebm_2026_rna_special?fr=sMjMyYTgzNTg2MzQ:
- Ends -
For more information please contact:
|
Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer |
Via Thalia Investor Hub |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke/Josh Ray (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Investor relations and Communications Sarah Hollins
Cohesion Bureau Investor relations and Communications Mary-Ann Chang |
Tel: +44 (0)20 7183 2463
Tel: +44 (0)7483 284853
|
About Thalia Therapeutics plc
Thalia Therapeutics is a pre-clinical biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat diseases at the source by silencing or modifying the genes that cause or contribute to them.
Our preclinical bispecific siRNA is a potentially long-acting treatment for atherosclerotic cardiovascular disease, which addresses two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
For further information visit www.thaliatx.com